Bleeding prediction by rotational thromboelastometry in chronic hemodialysis patients with non-valvular atrial fibrillation on apixaban

Table 1 Characteristics of patients classified into bleeding and no bleeding groups, n (%)

Characteristic clinical and epidemiologic	All patients (N = 19)	No Bleeding (n = 13)	Bleeding (n = 6)	P value
Age (year)	73 ± 12	73 ±12	74 ± 6	0.827
Sex (male = 1/females = 2)	13/6	9/4	4/2	0.911
Dialysis vintage (months)	4.56 ± 3.5	4.83 ± 0.9	4.0 ± 2.4	0.633
Body weight (kg)	83 ± 20	85 ± 20.	79 ± 21	0.513
Diabetes mellitus	7 (36.8)	5 (38.5)	2 (26.8)	0.829
Hypertension	12 (80)	9 (81.8)	3 (75)	0.770
Cardiac artery disease	5 (26.3)	4 (30.8)	1 (5.2)	0.516
Previous bleeding episodes	5 (26.3)	4 (30.8)	1 (5.2)	0.516
Stroke	4 (21.1)	2 (15.4)	2 (33.3)	0.372
Frailty scale	3.8 ± 1.8	3.8 ± 2.0	3.8 ± 1.5	0.944
Charlson Comorbidity Index	5.2 ± 1.3	5.2 ± 1.4	5.2 ± 1.0	0.933
Stroke/bleeding risk assessment (score)
CHA2DS2-VASc score	3 (2-5)	3 (2-5)	3 (2-4)	0.532
HAS-BLED score	3 (2-3)	2 (1.5-3)	3.5 (2.7-5.5)	0.070
ATRIA risk score	6 (5-8)	6 (3-7)	5.5 (5-8.5)	0.723
Modified hemodialysis score	1 (0-2)	1 (0-2)	1 (0.75-2)	0.550
Drugs
ACEIs/ARBs	8 (42.1)	7 (53.8)	1(5.2)	0.127
β-blockers	8 (42.1)	6 (46.2)	2 (33.3)	0.599
Antiarrhythmics	5 (26.3)	5 (38.5)	0 (0)	0.077
Statins	10 (52.6)	7 (53.8)	3 (30)	0.876
Acetylasalicylic acid/clopidogel	4 (21.1)	4 (30.8)	0 (0)	0.126

ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker.